Article

Three groups form alliance for retinal disease therapy

Bayer HealthCare of Leverkusen, Germany, has entered into an exclusive collaboration with Inception Sciences Inc. of San Diego and Versant Ventures of San Francisco to develop treatment options for patients with retinal diseases, such as wet age-related macular degeneration (AMD) and geographic atrophy (GA).

 

 

Leverkusen, Germany-Bayer HealthCare has entered into an exclusive collaboration with Inception Sciences Inc. of San Diego and Versant Ventures of San Francisco to develop treatment options for patients with retinal diseases, such as wet age-related macular degeneration (AMD) and geographic atrophy (GA).

Under the collaboration agreement, Inception Sciences and Bayer jointly will conduct early research in the area of ophthalmology under a newly created company called, “Inception 4.” The research will leverage Inception Science’s capabilities and combining scientific expertise to develop novel therapeutic agents in the area of ophthalmology.

Versant Ventures will provide equity funding to Inception 4 and Bayer will support the project through milestone payments. Bayer also will have an exclusive option to acquire Inception 4 under certain conditions.

Financial details of the agreement were not disclosed.

“We are excited to collaborate with Inception Sciences on the development of novel therapeutic agents in ophthalmology,” said Prof. Andreas Busch, director of Global Drug Discovery and member of the Executive Committee at Bayer HealthCare.

In addition to this collaboration, numerous substances addressing retinal eye diseases are currently investigated in early research stages at Bayer.

“Furthermore, we are working on a promising novel drug candidate with an alternative mode of delivery as an eye drop. If successfully developed and later on approved, this could provide a convenient treatment option for patients suffering from wet AMD,” Busch added.

“We are looking forward to partnering with Bayer and we share their enthusiasm for pursuing new pathways to address important medical needs in the field of ophthalmology,” said Peppi Prasit, PhD, chief executive officer at Inception Sciences. “Our partnership exemplifies the Build-to-Buy model for collaboration between Versant, Inception, and pharma partners for translating academic discoveries.”

For more articles in this issue of Ophthalmology Times eReport, click here.


 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.